menu
    • menu
    [{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"CYR212","moa":"IgG level","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cyrus Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Cyrus Biotechnology","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"IL-2 Mutein","moa":"IL-2 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cyrus Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyrus Biotechnology \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Cyrus Biotechnology \/ Selecta Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Cyrus Biotechnology

    Menu

    Cyrus Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cyrus Biotechnology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cyrus Biotechnology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYR212

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cyrus Biotechnology Selects CYR212 for Chronic Autoimmune Disease Treatment

                            Details : CYR212 to deplete circulating IgG, it has the potential to be the first approved IgG-lowering agent in myasthenia gravis and immune thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 09, 2025

                            Lead Product(s) : CYR212

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cyrus Biotechnology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cyrus Biotechnology

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IL-2 Mutein

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Selecta Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Protein...

                            Details : ImmTOR in combination with Treg-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing percentage and durability of Treg expansion for treatment of autoimmune diseases and other deleterious immune con...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            September 08, 2021

                            Lead Product(s) : IL-2 Mutein

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Selecta Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth